Quarterly report pursuant to Section 13 or 15(d)

Strategic Alliances (Details)

v3.21.1
Strategic Alliances (Details) - USD ($)
1 Months Ended 3 Months Ended 42 Months Ended 75 Months Ended
May 05, 2020
Oct. 21, 2019
Oct. 12, 2017
Sep. 30, 2018
May 31, 2016
Jan. 31, 2015
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Upfront payment from development and license agreement     $ 6,000,000              
Milestone revenue recognized             $ 790,000   $ 0  
Total revenues             $ 545,165,000 $ 211,466,000    
Pfizer | Products                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Milestone revenue recognized                   $ 0
Additional milestone payment to be received           $ 275,000,000.0        
Annual height velocity at point in time   12 months                
Non-refundable and non-creditable upfront payment           295,000,000.0        
Minimum | Pfizer | Products                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Each milestone payment           20,000,000.0        
Maximum | Pfizer | Products                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Each milestone payment           $ 90,000,000.0        
Pharmsynthez                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Ownership percentage, equity method             9.00%   9.00% 9.00%
Phase Two Initiation                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Upfront payment from development and license agreement       $ 6,000,000            
Regulatory and Development                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Milestone payment from development and license agreement     31,000,000              
Sales Revenue                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Milestone payment from development and license agreement     $ 75,000,000              
Transfer of intellectual property and other                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Total revenues             $ 4,269,000 9,553,000    
Transfer of intellectual property and other | Products                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Total revenues             3,000,000      
Transfer of intellectual property and other | Pfizer | Products                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Total revenues             2,800,000 8,700,000    
Products                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Total revenues             $ 33,945,000 $ 31,074,000    
Regulatory Milestones | EirGen Pharma Limited                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Maximum milestone payments $ 17,000,000                  
Sales Milestones | EirGen Pharma Limited                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Maximum milestone payments $ 210,000,000                  
Exclusive Option | VFMCRP                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Additional milestone payment to be received         $ 555,000,000